Search Results

You are looking at 51 - 60 of 263 items for :

  • "palliative care" x
  • All content x
Clear All
Full access

Jennifer W. Mack, Erin R. Currie, Vincent Martello, Jordan Gittzus, Asisa Isack, Lauren Fisher, Lisa C. Lindley, Stephanie Gilbertson-White, Eric Roeland, and Marie Bakitas

, University of Iowa, and University of California San Diego. Caregivers were asked to reflect on EoL care, including any ways that it could have better met the needs of AYAs. We specifically assessed barriers to the use of palliative care, hospice, and home

Full access

Lois Ramondetta

less than 10 months. Supportive/palliative care interventions are needed at diagnosis and recurrence. Honest, conflict-free conversations about potential for response and expectations are needed for women with recurrent disease to avoid treatments that

Full access

Alexandra K. Zaleta, Melissa F. Miller, Julie S. Olson, Eva Y.N. Yuen, Thomas W. LeBlanc, Craig E. Cole, Shauna McManus, and Joanne S. Buzaglo

attention to symptom assessment and management in routine cancer care. Studies of early integrated palliative care during active cancer treatment show that attending to symptoms improves patients’ overall QoL 31 – 33 and may lead to prolonged survival. 34

Full access

Amy Waller, Rob Sanson-Fisher, Nicholas Zdenkowski, Charles Douglas, Alix Hall, and Justin Walsh

-intensive, costly, and does not consistently meet patients' needs. Consequently, healthcare policies in many countries aim to reduce EOL hospital admissions and hospital mortality. 2 Despite the increasing availability of hospice facilities and palliative care (PC

Full access

Emily J. Martin, Eric J. Roeland, Madison B. Sharp, Carolyn Revta, James D. Murphy, Katherine E. Fero, and Heidi N. Yeung

pain within 30 days of discharge, consultations by the palliative care service, regular use (defined as an average of ≥2 doses daily) of intravenous or oral opioids while on PCA, and opioid-associated adverse events. Opioid-related adverse events were

Full access

Abdul-Rahman Jazieh, Hamdy A. Azim, Joan McClure, and Mohammad Jahanzeb

carcinoma, lym phoma, and palliative care. These committees included multidisciplinary expertise from different countries in the MENA region. Each committee comprised a chair and individual members with expertise in that area of oncology care, in addition

Full access

Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan, and Diane Portman

results highlight potential opportunities to improve palliative care. Despite these findings, there are gaps in understanding of the symptoms that patients perceive as most likely to benefit from cannabinoid use and the actual impact of cannabinoid

Full access

Bryan J. Schneider

Small cell lung cancer remains one of the more frustrating malignancies for oncologists to treat. Although responses to initial platinum-based chemotherapy are high, most are not durable, and many patients are candidates for further palliative chemotherapy. Therapeutic options include reinduction or single-agent chemotherapy, depending on the duration of response to front-line treatment. Topotecan is the only approved agent for patients with relapsed disease. Several phase II studies have shown a modest benefit with other agents used today, although combination chemotherapy should be avoided because of increased toxicity. Palliative care should always be the focus, especially in patients with recurrent or chemorefractory small cell lung cancer and a poor performance status.

Full access

St. Jude Children's Research Hospital

An estimated 33,370 people will die of pancreatic cancer in the United States in 2007, making it the fourth most common cause of cancer-related death among men in the United States. Although incidence is roughly equal among men and women, African Americans appear to have a higher incidence of pancreatic cancer than white Americans. The NCCN Pancreatic Adenocarcinoma Guidelines discuss risk factors, diagnosis and staging, and treatment through palliative care or surveillance for patients with tumors of the exocrine pancreas. Overall, in view of the poor outcome of patients with all stages of pancreatic cancer, the NCCN panel recommends that investigational options be considered in all phases of disease management. Specific palliative measures are recommended for patients with advanced pancreatic adenocarcinoma characterized by biliary or gastric obstruction, severe abdominal pain, or other tumor-associated manifestations of the disease.

For the most recent version of the guidelines, please visit NCCN.org

Full access

UCSF Helen Diller Family Comprehensive Cancer Center

Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.

For the most recent version of the guidelines, please visit NCCN.org